Latest 10-Q quarterly reports

Magellan Copper & Gold Corp. filed its Q2 2026 Form 10-Q, detailing continued operating losses, a significant accumulated deficit, and substantial doubt regarding its ability to continue as a going concern.

Protara Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing advancements in its TARA-002 and IV Choline Chloride programs, alongside financial performance and corporate updates.

LB Pharmaceuticals Inc. reported a substantial increase in research and development expenses and a widening net loss for the second quarter of 2026, driven by ongoing clinical trials for its lead product candidate, LB-102.

Coya Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing research and development efforts, increased operating expenses, and a continued net loss, while highlighting the need for future capital.

Prelude Therapeutics Incorporated announced its financial results for the second quarter ended June 30, 2026, highlighting progress in its oncology pipeline and a significant capital raise.

Smithfield Foods announced its Q2 2026 results, showcasing increased net income and operating profit, driven by strategic initiatives and improved segment performance.

Theravance Biopharma announced a definitive agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash, plus a contingent value right, following a strategic review.

DPC Holdings PLC announced its second quarter 2026 financial results, highlighting revenue growth driven by the aerospace and IGT sectors, but also reporting a significant increase in net loss primarily due to a substantial rise in management incentive plan expenses.

Big Sky Industrial Inc. (BSIN) filed its Q2 2026 Form 10-Q, reporting a net loss of $2.3 million, with revenues impacted by declining oil and gas production but bolstered by higher oil prices.

Zura Bio Limited reported a net loss of $26.3 million for Q2 2026, with increased R&D expenses, while maintaining a substantial cash balance of $205.1 million.

Sagimet Biosciences Inc. reported a substantial increase in cash and cash equivalents following a $175 million underwritten offering, while also detailing progress in its clinical-stage drug development programs for acne and MASH.

C4 Therapeutics has entered into a significant research collaboration and license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop degrader-antibody conjugates (DACs).

908 Devices Inc. announced its Q2 2026 results, showcasing a 23% year-over-year revenue increase to $16.1 million, driven by product sales, alongside improved gross margins, while continuing to manage net losses.

Intensity Therapeutics reports continued net losses and operational challenges, raising substantial doubt about its ability to continue as a going concern, despite advancements in its clinical trial programs.

Xtant Medical Holdings, Inc. reported a significant decrease in revenue for the second quarter of 2026, primarily due to divestitures and the loss of license revenue, alongside a substantial operating expense write-off.

Aura Biosciences reports increased R&D and G&A expenses in Q2 2026, announces a 20% workforce reduction to focus on ocular oncology, and highlights progress in bel-sar clinical trials.

Tango Therapeutics announced promising efficacy data for its vopimetostat combination therapy in pancreatic cancer, alongside significant increases in R&D spending and continued net losses, highlighting ongoing capital requirements.

Kardigan, Inc. details advancements in its cardiovascular drug pipeline, successful IPO, and robust cash position, while acknowledging ongoing development risks.

Upstream Bio, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical trial progress for its lead candidate, verekitug, while reporting continued net losses and a substantial accumulated deficit.

Vestis Corporation's Q3 2026 results show a significant increase in operating income and net income, driven by successful cost-saving measures and operational efficiencies, despite a marginal decrease in revenue.

NeurAxis, Inc. announced a significant increase in net sales and gross profit for the second quarter of 2026, driven by expanded insurance coverage for its IB-Stim device.

Chicago Atlantic Real Estate Finance reported a decrease in net income and net interest income for Q2 2026, alongside a substantial rise in credit loss provisions, while progressing with its merger with Chicago Atlantic BDC, Inc.

Immunic, Inc. (IMUX) filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development for its lead multiple sclerosis drug candidate, vidofludimus calcium, while reporting increased operating expenses and a net loss.

Shattuck Labs, Inc. (STTK) announced positive Phase 1 data for its lead candidate SL-325, demonstrating a favorable safety profile and complete receptor occupancy, while also reporting increased cash reserves from recent financings.

Twenty One Capital, Inc. filed its Q2 2026 Form 10-Q, detailing a substantial net loss driven by a significant decrease in the fair value of its Bitcoin holdings, alongside changes in executive leadership.

Ampco-Pittsburgh Corporation's Q2 2026 filing shows a significant improvement in operating income driven by the Air and Liquid Processing segment, alongside a growing backlog, despite a dip in net sales.

DarioHealth Corp. announced its second-quarter 2026 financial results, showing a decrease in total revenues and a continued net loss, though operating expenses were reduced.

Scientist Home Future Health Limited reported increased revenues for the six months ended June 30, 2026, but also significant net losses and a substantial decrease in cash, raising going concern doubts.

Team, Inc. announced its Q2 2026 financial results, reporting a net loss of $6.812 million on revenues of $228.678 million, a decrease from the prior year.

Oramed Pharmaceuticals Inc. filed its Form 10-Q for the period ended June 30, 2026, reporting substantial financial income driven by investment revaluations, alongside an operating loss.